Avi Biopharma, Inc.

Seattle Biomedical Research Institute

Sarepta Therapeutics, Inc.

Stephen H Bartelmez

Patrick L Iversen

Frank Ruscetti

Ewa Sitnicka

A composition antisense oligomer directed to an mRNA preferentially expressed together with methods for treating stem cells with such a composition to increase the number of lineage committed progenitor cells and their progeny, and/or slow the growth of cancer cells. Also described is the use of such compositions and antisense oligonucleotide-treated stem cells in methods for treatment of cancer.

Antisense compositions and cancer-treatment methods

The invention relates to TGF-&#x3b2; blocking agent-treated HSC compositions and methods comprising the same. The TGF-&#x3b2; blocking agent-treated stem cells are viable for an extended time in culture without replication or differentiation and upon transfer to appropriate conditions are capable of long term hematopoietic reconstitution.

Transforming growth factor beta (TGF-&#x3b2;) blocking agent-treated stem cell composition and method

The invention relates to stem cell compositions comprising anti-TGF-&bgr; treated stem cells which are viable for at least 14 days in culture without replication or differentiation and methods for rapid and long term in vitro hematopoiesis and in vivo hematopoietic reconstitution using such anti-TGF-&bgr; treated stem cells.

Growing community of inventors

Seattle, WA, United States of America

Stephen H Bartelmez